These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 8956684)

  • 61. Red blood cell membrane dynamics in schizophrenia. I. Membrane fluidity.
    Yao JK; van Kammen DP
    Schizophr Res; 1994 Feb; 11(3):209-16. PubMed ID: 8193060
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Haloperidol: therapeutic window in schizophrenia.
    Palao DJ; Arauxo A; Brunet M; Bernardo M; Haro JM; Ferrer J; Gonzalez-Monclus E
    J Clin Psychopharmacol; 1994 Oct; 14(5):303-10. PubMed ID: 7806684
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Further evidence of a dose-response threshold for haloperidol in psychosis.
    Stone CK; Garve DL; Griffith J; Hirschowitz J; Bennett J
    Am J Psychiatry; 1995 Aug; 152(8):1210-2. PubMed ID: 7625474
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Serum level monitoring and therapeutic effect of haloperidol in schizophrenic patients.
    Moulin MA; Davy JP; Debruyne D; Andersson JC; Bigot MC; Camsonne R; Poilpré E
    Psychopharmacology (Berl); 1982; 76(4):346-50. PubMed ID: 6812109
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Risperidone in the treatment of schizophrenia.
    Marder SR; Meibach RC
    Am J Psychiatry; 1994 Jun; 151(6):825-35. PubMed ID: 7514366
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Absence of relationship of serum haloperidol concentration and clinical response in chronic schizophrenia: a fixed-dose study.
    Bigelow LB; Kirch DG; Braun T; Korpi ER; Wagner RL; Zalcman S; Wyatt RJ
    Psychopharmacol Bull; 1985; 21(1):66-8. PubMed ID: 3983341
    [No Abstract]   [Full Text] [Related]  

  • 67. Mutability and relationship between positive and negative symptoms during neuroleptic treatment in schizophrenia.
    Tandon R; Goldman RS; Goodson J; Greden JF
    Biol Psychiatry; 1990 Jun; 27(12):1323-6. PubMed ID: 2364120
    [No Abstract]   [Full Text] [Related]  

  • 68. Serum level of haloperidol and its clinical significance.
    Itoh H; Yagi G; Ohtsuka N; Iwamura K; Ichikawa K
    Prog Neuropsychopharmacol; 1980; 4(2):171-83. PubMed ID: 7403350
    [No Abstract]   [Full Text] [Related]  

  • 69. Early antipsychotic response to resumption of neuroleptics in drug-free chronic schizophrenic patients.
    Glovinsky D; Kirch DG; Wyatt RJ
    Biol Psychiatry; 1992 May; 31(9):968-70. PubMed ID: 1637936
    [No Abstract]   [Full Text] [Related]  

  • 70. Plasma haloperidol and reduced haloperidol concentrations in a geriatric population.
    Chang WH; Jann MW; Chiang TS; Lin HN; Hu WH; Chien CP
    Neuropsychobiology; 1996; 33(1):12-6. PubMed ID: 8821369
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study.
    de Haan L; van Bruggen M; Lavalaye J; Booij J; Dingemans PM; Linszen D
    Am J Psychiatry; 2003 Feb; 160(2):303-9. PubMed ID: 12562577
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Positive and negative symptoms: is their change related?
    Czobor P; Volavka J
    Schizophr Bull; 1996; 22(4):577-90. PubMed ID: 8938912
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia.
    Wright P; Birkett M; David SR; Meehan K; Ferchland I; Alaka KJ; Saunders JC; Krueger J; Bradley P; San L; Bernardo M; Reinstein M; Breier A
    Am J Psychiatry; 2001 Jul; 158(7):1149-51. PubMed ID: 11431240
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Serum haloperidol concentration and clinical response in schizophrenia.
    Kirch DG; Bigelow LB; Korpi ER; Wagner RL; Zalcman S; Wyatt RJ
    Schizophr Bull; 1988; 14(2):283-9. PubMed ID: 3201181
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Hydroxyhaloperidol and clinical outcome in schizophrenia.
    Altamura AC; Mauri M; Cavallaro R; Regazzetti MG; Bareggi SR
    Psychopharmacol Ser; 1989; 7():263-8. PubMed ID: 2594731
    [No Abstract]   [Full Text] [Related]  

  • 76. Clinical state, plasma levels of haloperidol and prolactin: a correlation study in chronic schizophrenia.
    Rao VA; Bishop M; Coppen A
    Br J Psychiatry; 1980 Dec; 137():518-21. PubMed ID: 7214106
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The relationship between haloperidol blood levels and clinical responses.
    Itoh H; Yagi G; Fujii Y; Iwamura K; Ichikawa K
    Prog Neuropsychopharmacol Biol Psychiatry; 1984; 8(2):285-92. PubMed ID: 6539935
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Heterogeneity of schizophrenia: relationship to latency of neuroleptic response.
    McDermott BE; Sautter FJ; Garver DL
    Psychiatry Res; 1991 Apr; 37(1):97-103. PubMed ID: 1862165
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Clinical action of remoxipride.
    Conley R; Tamminga CA; Nguyen JA
    Arch Gen Psychiatry; 1994 Dec; 51(12):1001. PubMed ID: 7979877
    [No Abstract]   [Full Text] [Related]  

  • 80. D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate.
    Nyberg S; Farde L; Halldin C; Dahl ML; Bertilsson L
    Am J Psychiatry; 1995 Feb; 152(2):173-8. PubMed ID: 7840348
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.